This article provides a factual comparison of BPC-157 and TB-500 across their structure, mechanisms, published research, and why they are often studied together
For retatrutide , the 2023 New England Journal of Medicine phase 2 trial used doses of up to 12 mg weekly, with a structured escalation schedule beginning at lower doses and increasing incrementally over a period of weeks
Get Started Schedule a consultation with our medical team to learn if DSIP peptide therapy is right for your sleep optimization and wellness goals
Users may experience water retention, heightened hunger, and alterations in insulin response
Phase 2 trials showed up to 24% body weight reduction at the highest dose, and Phase 3 data from the TRIUMPH program pushed that number even higher, reaching 28.7% in participants with obesity and knee osteoarthritis